Jim Cramer sits down with Salesforce.com chief Marc Benioff, who speaks to his company's newly forged deal with Apple.
Jim Cramer explains why investors shouldn't let caution trick you into missing straightforward moves.
Jim Cramer rattles off his take on callers' favorite stocks, including a high-profile auto play with a heavy trading volume.
Jim Cramer gets the latest on cybersecurity from FireEye CEO Kevin Mandia, whose company was hired by Google to defend against state-sponsored cyberattacks.
Jim Cramer hears from Salesforce.com co-founder, Chairman and co-CEO Marc Benioff, who explains why he and his wife purchased Time Magazine.
Jim Cramer breaks down the weakness in the semiconductor stock cohort.
Jim Cramer makes a case for maintaining a long-term outlook in this market.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including an oil play that's benefiting from the current market layout.
Jim Cramer says that while his "humanization of pets" thesis remains intact, the newly public Elanco Animal Health is not the way to play it.
Jim Cramer sits down with J.P. Morgan Chase & Co. Chairman and CEO Jamie Dimon, who speaks to the current political climate, why he won't run and his vision for government.
Jim Cramer defends Comcast's long-term track record despite the media giant's share drop in the wake of winning the bidding war for Sky.
Jim Cramer zooms through his take on callers' favorite stocks, including a small independent energy play that he wouldn't recommend to investors.
Jim Cramer explains how a demand for Micron's chips combined with its buyback could send the company soaring.
Jim Cramer sits down with Q6 Cyber founder and CEO Eli Dominitz, who says companies that think their mission is to stop attacks in real time are "dead wrong."
Jim Cramer hears from Red Hat President and CEO Jim Whitehurst, who addresses his company's second-quarter revenue miss.
Jim Cramer shares his game plan for the week ahead and explains why tariffs may not weigh on stocks as much as investors think.
Jim Cramer details what the rotation out of growth and into value means for the bull market.
Jim Cramer flies through his take on callers' favorite stocks, including a high-profile social media play.
Jim Cramer sits down with Yuval Cohen, the CEO of a company that is creating treatments derived from manmade cannabinoids for rare diseases like cystic fibrosis.
Jim Cramer doubles down on his warning about investing in marijuana stocks like Tilray, which has been trading wildly since CEO Brendan Kennedy's appearance on "Mad Money."
Data also provided by 
